A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 3, 2015, Pages 517-523

  Fan, Yun ^a   Huang, Zhiyu ^a   Fang, Luo ^a   Miao, Lulu ^a   Gong, Lei ^a   Yu, Haifeng ^a   Yang, Haiyan ^a   Lei, Tao ^a   Mao, Weimin ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Brain metastases; Cerebrospinal fluid; Icotinib; Non small cell lung cancer; Whole brain radiotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC METAL COMPLEX; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; ICOTINIB; PEMETREXED; TAXANE DERIVATIVE; CROWN ETHER; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN METASTASIS; BRAIN RADIATION; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINESE; CLINICAL ARTICLE; COGNITIVE DEFECT; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENE MUTATION; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LONG TERM SURVIVAL; LUNG ADENOCARCINOMA; MALE; MEMORY DISORDER; NAUSEA AND VOMITING; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION SICKNESS; SIDE EFFECT; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL TIME; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE; TUMOR GROWTH; WHOLE BRAIN RADIOTHERAPY; BLOOD; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CEREBROSPINAL FLUID; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SECONDARY;

ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CROWN ETHERS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES;

EID: 84939562715     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2760-5     Document Type: Article

References (24)

1. Sørensen JB, Hansen HH, Hansen M, Dombernowsky P (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6:1474-1480
2. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H (2007) Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 242(3):882-888
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer surveillance system. J Clin Oncol 22:2865-2872
4. Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP (2008) A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys 71:79-86
5. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751
6. Khuntia D, Brown P, Li J et al (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295-1304
7. Shepherd FA, Pereira JR, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123-132
8. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
9. Togashi Y, Masago K, Masuda S et al (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70:399-405
10. Wu YL, Zhou C, Cheng Y et al (2011) Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Lancet Oncol. 12:735-742
11. Ceresoli GL, Cappuzzo F, Gregorc V et al (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 15:1042-1047
12. Welsh JW, Komaki R, Amini A et al (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31:895-902
13. Kim JE, Lee DH, Choi Y et al (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastases. Lung Cancer 65:351-354
14. Iuchi T, Shingyoji M, Sakaida T et al (2013) Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 82:282-287
15. Chinnaiyan P, Huang S, Vallabhaneni G et al (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65:3328-3335
16. Tan F, Shen X, Wang D et al (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 76:177-182
17. Shi Y, Zhang L, Liu X et al (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 14:953-961
18. Namba Y, Kijima T, Yokota S et al (2004) Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer. 6:123-128
19. Garassino MC, Martelli O, Broggini M et al (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 14:981-988
20. Kawaguchi T, Ando M, Asami K et al (2014) Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 32:1902-1908
21. Zhou Q, Cheng Y, Yang JJ et al (2014) Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Ann Oncol 25:2385-2391
22. Lee JK, Hahn S, Kim DW et al (2014) Epidermal growth factor receptor tyrosine kinase inhibitors vs. conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA 311:1430-1437
23. Soon YY, Leong CN, Koh WY et al (2015) EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol 114(2):167-172
24. Icotinib treat the patient with brain metastases epidermal growth factor receptor (EGFR) mutant non small cell lung cancer comparing with whole brain radiotherapy. http://www.ClinicalTrials.gov (NCT01724801)